Dacomitinib (Standard)
Dacomitinib (Standard) (PF-00299804 (Standard); PF-299804 (Standard)) is the analytical standard of Dacomitinib (HY-13272). This product is intended for research and analytical applications. Dacomitinib is an orally active irreversible pan-ERBB receptor tyrosine kinase inhibitor with inhibitory activity against HER1/EGFR, HER2, and HER4. Dacomitinib exerts antitumor effects in various tumor cells, inhibiting tumor cell proliferation, migration, and invasion, inducing cell cycle arrest and apoptosis, regulating the expression of molecules related to the cell cycle, apoptosis, and epithelial-mesenchymal transition, and it can also reverse partial drug resistance, producing synergistic effects when combined with chemotherapy. Dacomitinib inhibits key signaling pathways such as PI3K‑AKT‑mTOR and PLK1‑FOXM1. Dacomitinib ameliorates pathological changes associated with pulmonary arterial hypertension in rats. Dacomitinib can be used in research on breast cancer, bladder cancer, epithelial ovarian cancer, and pulmonary arterial hypertension.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98%
- CAS No.: 1110813-31-4
- Formule: C24H25ClFN5O2
- Masse moléculaire:469.94
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Pureté et documentation
-
Help & FAQs
-
HY-13272
DacomitinibPan-ERBB Receptor Inhibitor -
HY-15772
OsimertinibMutant-Selective EGFR Inhibitor -
HY-50895
GefitinibEGFR Inhibitor -
HY-50896
ErlotinibEGFR Tyrosine Kinase Inhibitor -
HY-50898
LapatinibEGFR/HER2 Inhibitor -
HY-12000
AG490EGFR Inhibitor -
HY-15772R
Osimertinib (Standard)Mutant-Selective EGFR Inhibitor -
HY-32721
NeratinibHER2/EGFR Inhibitor -
HY-15730
PoziotinibEGFR Inhibitor -
HY-10045
AEE788EGFR/ErbB2 Inhibitor -
HY-13524
AG-1478EGFR Inhibitor -
HY-16558
ButeinEGFR/PDE Inhibitor
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 1110813-31-4
-
Masse moléculaire 469.94
-
Formule C24H25ClFN5O2
-
SMILES
O=C(/C=C/CN1CCCCC1)NC2=CC3=C(C=C2OC)N=CN=C3NC4=CC=C(C(Cl)=C4)F
-
Synonyms
PF-00299804 (Standard); PF-299804 (Standard)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[4]. Shirley M, et al. Dacomitinib: First Global Approval. Drugs. 2018 Dec;78(18):1947-1953.
[5]. Kalous O, et al. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. Molecular cancer therapeutics. 2012 Sep;11(9):1978-87. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Dacomitinib (Standard) Related Classifications
HY-13272R Related Classifications
Powered by Bioz
Keywords
- Dacomitinib (Standard)
- 1110813-31-4
- PF-00299804 (Standard)
- PF-299804 (Standard)
- Reference Standards
- EGFR
- IAP
- Akt
- ERK
- PI3K
- Survivin
- Caspase
- CDK
- Apoptosis
- Epidermal growth factor receptor
- ErbB-1
- HER1
- PKB
- Protein kinase B
- Extracellular signal regulated kinases
- Phosphoinositide 3-kinase
- Cyclin dependent kinase
- HER2-amplified breast cancer
- pulmonary arterial hypertension
- AsPC-1
- pancreatic ductal adenocarcinoma
- epithelial ovarian cancer
- PaTu 8902
- pan-ERBB receptor tyrosine kinase inhibitor
- PANC-1
- non-small cell lung cancer
- bladder cancer
- Inhibitor
- inhibitor
- inhibit